DHA supplementation for late onset Stargardt disease: NAT-3 study
Giuseppe Querques1, Pascale Benlian1, Bernard Chanu2, Nicolas Leveziel1, Gabriel Coscas1, Gisele Soubrane1, Eric H Souied11Department of Ophthalmology, University of Paris XII, Centre Hospitalier Intercommunal de Creteil, 2Department of Nutrition, University of Paris XII, Hopital Henry Mondor, Crete...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2010
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/28cc8b05d1124a96ac01f8c05cab7d83 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:28cc8b05d1124a96ac01f8c05cab7d83 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:28cc8b05d1124a96ac01f8c05cab7d832021-12-02T04:31:59ZDHA supplementation for late onset Stargardt disease: NAT-3 study1177-54671177-5483https://doaj.org/article/28cc8b05d1124a96ac01f8c05cab7d832010-06-01T00:00:00Zhttp://www.dovepress.com/dha-supplementation-for-late-onset-stargardt-disease-nat-3-study-a4677https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Giuseppe Querques1, Pascale Benlian1, Bernard Chanu2, Nicolas Leveziel1, Gabriel Coscas1, Gisele Soubrane1, Eric H Souied11Department of Ophthalmology, University of Paris XII, Centre Hospitalier Intercommunal de Creteil, 2Department of Nutrition, University of Paris XII, Hopital Henry Mondor, Creteil, FranceBackground: We analyzed the effects of a docosahexaenoic acid (DHA) supplementation in patients affected with late onset Stargardt disease (STGD).Methods: DHA (840 mg/day) was given to 20 STGD patients for six months. A complete ophthalmologic examination, including best-corrected visual acuity (BCVA) and multifocal electroretinogram (mfERG), was performed at inclusion day 0 (D0) and at month 6 (M6).Results: Overall, no statistical differences have been observed at M6 vs D0 as regards BCVA and mfERG (P > 0.05). Mild Improvement of BCVA and improvement of mfERG was noted in seven/40 eyes of four/20 patients. In the first patient, the peak of the a wave increased from 66 nV/deg² to 75.4 nV/deg² in the right eye (RE) and 24.5 nV/deg² to 49.1 nV/deg² in the left eye (LE). The peak of the b wave improved from 122 nV/deg² to 157 nV/deg² in the RE, and 102 nV/deg² to 149 nV/deg² in the LE. In the second patient peaks of the a and b waves respectively increased from 11.8 nV/deg² to 72.1 nV/deg² and 53 nV/deg² to 185 nV/deg² in the RE. In the third patient the peak of the a wave increased from 37 nV/deg² to 43 nV/deg² in the RE, and from 31 nV/deg² to 45 nV/deg² in the LE; the peak of the b wave improved from 70 nV/deg² to 89 nV/deg² in the RE, and from 101 nV/deg² to 108 nV/deg² in the LE. In the fourth patient, the peak of the a wave increased from 39 nV/deg² to 42 nV/deg² in the RE, and from 40 nV/deg² to 43 nV/deg² in the LE; the peak of the b wave improved from 86 nV/deg² to 94 nV/deg² in the RE, and from 87 nV/deg² to 107 nV/deg² in the LE.Conclusion: DHA seems to influence some functional parameters in patients affected with STGD. However, no short-term benefit should be expected from DHA supplementation. Keywords: docosahexaenoic acid (DHA), multifocal electroretinogram, omega-3, polyunsaturated fatty acid, retinal dystrophy, Stargardt disease Giuseppe QuerquesPascale BenlianBernard Chanuet alDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2010, Iss default, Pp 575-580 (2010) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Ophthalmology RE1-994 |
| spellingShingle |
Ophthalmology RE1-994 Giuseppe Querques Pascale Benlian Bernard Chanu et al DHA supplementation for late onset Stargardt disease: NAT-3 study |
| description |
Giuseppe Querques1, Pascale Benlian1, Bernard Chanu2, Nicolas Leveziel1, Gabriel Coscas1, Gisele Soubrane1, Eric H Souied11Department of Ophthalmology, University of Paris XII, Centre Hospitalier Intercommunal de Creteil, 2Department of Nutrition, University of Paris XII, Hopital Henry Mondor, Creteil, FranceBackground: We analyzed the effects of a docosahexaenoic acid (DHA) supplementation in patients affected with late onset Stargardt disease (STGD).Methods: DHA (840 mg/day) was given to 20 STGD patients for six months. A complete ophthalmologic examination, including best-corrected visual acuity (BCVA) and multifocal electroretinogram (mfERG), was performed at inclusion day 0 (D0) and at month 6 (M6).Results: Overall, no statistical differences have been observed at M6 vs D0 as regards BCVA and mfERG (P > 0.05). Mild Improvement of BCVA and improvement of mfERG was noted in seven/40 eyes of four/20 patients. In the first patient, the peak of the a wave increased from 66 nV/deg² to 75.4 nV/deg² in the right eye (RE) and 24.5 nV/deg² to 49.1 nV/deg² in the left eye (LE). The peak of the b wave improved from 122 nV/deg² to 157 nV/deg² in the RE, and 102 nV/deg² to 149 nV/deg² in the LE. In the second patient peaks of the a and b waves respectively increased from 11.8 nV/deg² to 72.1 nV/deg² and 53 nV/deg² to 185 nV/deg² in the RE. In the third patient the peak of the a wave increased from 37 nV/deg² to 43 nV/deg² in the RE, and from 31 nV/deg² to 45 nV/deg² in the LE; the peak of the b wave improved from 70 nV/deg² to 89 nV/deg² in the RE, and from 101 nV/deg² to 108 nV/deg² in the LE. In the fourth patient, the peak of the a wave increased from 39 nV/deg² to 42 nV/deg² in the RE, and from 40 nV/deg² to 43 nV/deg² in the LE; the peak of the b wave improved from 86 nV/deg² to 94 nV/deg² in the RE, and from 87 nV/deg² to 107 nV/deg² in the LE.Conclusion: DHA seems to influence some functional parameters in patients affected with STGD. However, no short-term benefit should be expected from DHA supplementation. Keywords: docosahexaenoic acid (DHA), multifocal electroretinogram, omega-3, polyunsaturated fatty acid, retinal dystrophy, Stargardt disease |
| format |
article |
| author |
Giuseppe Querques Pascale Benlian Bernard Chanu et al |
| author_facet |
Giuseppe Querques Pascale Benlian Bernard Chanu et al |
| author_sort |
Giuseppe Querques |
| title |
DHA supplementation for late onset Stargardt disease: NAT-3 study |
| title_short |
DHA supplementation for late onset Stargardt disease: NAT-3 study |
| title_full |
DHA supplementation for late onset Stargardt disease: NAT-3 study |
| title_fullStr |
DHA supplementation for late onset Stargardt disease: NAT-3 study |
| title_full_unstemmed |
DHA supplementation for late onset Stargardt disease: NAT-3 study |
| title_sort |
dha supplementation for late onset stargardt disease: nat-3 study |
| publisher |
Dove Medical Press |
| publishDate |
2010 |
| url |
https://doaj.org/article/28cc8b05d1124a96ac01f8c05cab7d83 |
| work_keys_str_mv |
AT giuseppequerques dhasupplementationforlateonsetstargardtdiseasenat3study AT pascalebenlian dhasupplementationforlateonsetstargardtdiseasenat3study AT bernardchanu dhasupplementationforlateonsetstargardtdiseasenat3study AT etal dhasupplementationforlateonsetstargardtdiseasenat3study |
| _version_ |
1718401173609775104 |